

## **Zetiq Technologies and Biomics Biotechnologies Sign Collaboration Agreement**

### **Collaboration agreement for the development and commercialization of CellDetect<sup>®</sup>, a novel screening and diagnosis technology of cervical cancer**

Ramat Gan, Israel, and Nantong, China December 14<sup>th</sup>, 2009 – [Zetiq Technologies Ltd.](#), of the Israeli based Bio-Light Group (TASE: BOLT) developing cancer screening and diagnostic products, and Biomics Biotechnologies, a prominent Chinese company engaging in the development and sales of medical and diagnostic products, announce that they have signed a collaboration agreement for the development and commercialization of the CellDetect<sup>®</sup> technology towards the diagnosis of cervical cancer.

According to the agreement, Biomics Biotechnologies will receive exclusive rights to distribute market and sell the CellDetect<sup>®</sup> cervical cancer diagnosis technology in China. Biomics Biotechnologies will take responsibility for the registration and regulatory approval process with the SFDA, the medical regulatory authority in China. Zetiq Technologies will supply the required components of the technology and assist in the regulatory process. In addition, the companies will collaborate to co-develop a color discrimination automated scanning device.

Upon successful completion of the development activities and regulatory approval, Biomics Biotechnologies will be granted exclusive rights to distribute the product for a period of 5 years in China. Zetiq Technologies will receive an aggregate amount of \$500,000 thousand based on the successful sale achievement of the CellDetect<sup>®</sup> product. In addition, Biomics Biotechnologies will pay Zetiq Technologies royalties at the rate of 16% on direct sales of the product generated by Biomics, or 25% royalties of the income of Biomics Biotechnologies from sales generated by any sub-distributor.

Zetiq Technologies and Biomics Biotechnologies have initiated a process towards applying for partial funding of the collaboration through the Israel China Bi-national fund. It is anticipated that this partnership will significantly increase the development of the CellDetect<sup>®</sup> and additional products, as well as, lead to the implementation of the technology in additional markets around the world.

The CellDetect<sup>®</sup> technology can differentiate by color and morphology between normal cells and a wide range of cancer conditions. The color discrimination is excellently exemplified in controlled tissue culture experiments showing that while cancer cells are stained red by the

CellDetect<sup>®</sup> technology, treatment of the same cells with chemicals known to affect the cancer "phenotype" causes these cells to stain green. In human tissue sections, the CellDetect<sup>®</sup> readily differentiated normal cells and tissues from neoplastic cells and tissues by both color and morphology.

"This agreement represents a significant opportunity for ZetiQ and we are confident that our CellDetect<sup>®</sup> will increase the efficiency for detecting and monitoring cervical cancer. Cervical cancer is the second most common cancer among women worldwide and a major medical problem in China, with a dire need for an effective solution towards cervical screening "says Dr. **Adi Elkeles**, CEO of ZetiQ Technologies."We believe that Biomics Biotechnologies has outstanding capabilities in commercializing our product in China and we are delighted to be working with them to make our products available to the Chinese market, adds Dr. Elkeles."This step is important to our pipeline and reinforces our commitment to improving the screening and diagnosis technologies available for identifying cervical cancer."

Dr. Ami Eyal, CEO of Bio-Light, "Biomics Biotechnologies are leaders in our respective market categories and we are pleased to partner with such a significant company. This collaboration strengthens the distribution channel of ZetiQ Technologies innovative CellDetect technology in the Asian market, complementing our overall advancement in the field."

"There is a long friendship history between Israel and China. We are pleased to collaborate with an Israeli company like ZetiQ Technologies which was founded by a group of experienced pathologists. My experience as a medical doctor helped us build a good technical communication channel which is the bridge to this collaboration." said Dr. York Zhu, Founder and CEO of Biomics.

"ZetiQ Technologies' technical innovation, Biomics Biotech's scientific research capability and international business sense is our solid foundation of this collaboration. With efforts of both sites, we believe there will be a bright future of this collaboration", added Dr. Zhu.

#### About ZetiQ Technologies Ltd.

ZetiQ Technologies Ltd. is a subsidiary of Bio-Light, Israeli Life Sciences Investments Ltd., a management and holding company specializing in developing Life Sciences developments. Bio-Light is traded on the Israeli Stock Exchange under the symbol TASE: BOLT.

ZetiQ Technologies is a leading Israeli based developer of proprietary tools for screening, monitoring and diagnosing cancer. The company's novel technology CellDetect<sup>®</sup> enables the detection and

diagnosis of cancer by differential staining of cancer cells and detecting a wide range of cancer conditions.

#### About Biomics Biotechnologies

Biomics Biotechnologies (Nantong) Co., Ltd. (Biomics) is a leading RNAi therapeutical technology, developing and selling medical and diagnostic products. The company has a combined platform of full-sites siRNA library, drug targets screening and identification, siRNA structure modification and drug delivery systems. The company is managed by numerous professionals with international experience, and is funded by York Zhu, a Chinese-American Scientist.

#### **For more information, please contact:**

**Yamit Nissanov, Media Contact**  
**+972-9-9514666, +972-52-5541810**  
[yamit@idancom.com](mailto:yamit@idancom.com)

###